The covalent conjugation of potent cytotoxic agents to either macromolecular carriers or
small molecules represents a well‐known approach to increase the therapeutic index of …

Ru (II) polypyridyl complexes have gained widespread attention as photosensitizers for
photodynamic therapy (PDT). Herein, we systematically investigate a series of the type [Ru …

Accurate diagnosis and therapy are challenging because most diseases lack a single
biomarker that distinguishes them from other disorders. A solution would enhance targeting …

Theranostics has attracted great attention due to its ability to combine the real-time
diagnosis of cancers with efficient treatment modalities. Activatable dual-functional …

The development of molecular theranostic prodrugs for in vivo cancer diagnosis and
targeted chemotherapy is urgently required. Enzyme‐activated prodrugs display superior …

Tumor hypoxia renders treatments ineffective that are directly (eg, radiotherapy and
photodynamic therapy) or indirectly (eg, chemotherapy) dependent on tumor oxygenation …

We report herein, an azo-derivative (AzP1) of FDA approved antineoplastic drug SN-38
(irinotecan analogue) as a theranostic agent with a potential for both tumor hypoxia-specific …

Hypoxia presents a challenge to anticancer therapy, reducing the efficacy of many available
treatments. Photodynamic therapy is particularly susceptible to hypoxia, given that its …

The precisely spatial‐temporal delivery of heterogeneous payloads from a single system
with the same pulse is in great demand in realizing versatile and synergistic functions. Very …

Despite the fact that photodynamic therapy (PDT) has promising clinical prospects, its
therapeutic efficacy is still restricted by the hypoxic tumor microenvironment (TME) …